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February 2016 Abstracts S37vomiting (25%), and fatigue (23%). Most AEs were
Grade (G) 1-2. The G3 treatment-related AEs were rash
(6 pts), fatigue (1 pt), decreased appetite (1 pt), dehy-
dration (1 pt), pruritus (1 pt), and face edema (1 pt). In
particular, no G3 treatment-related gastrointestinal
toxicity or liver enzyme elevation has been reported. To
date, 24 ALKþ NSCLC pts treated at doses  200 mg are
evaluable for response; partial response (PR) was
achieved in 16 pts (67%) and stable disease (SD) in 3 pts
(13%). In the crizotinib-naïve pts (n¼8), responses were
observed in 6 pts (75%) and SD in 1 pt (13%). In the 12
pts with prior crizotinib but no other ALK TKI, 10 pts
(83%) achieved PR and 1 (8%) SD. CNS responses have
been observed in both crizotinib naïve and crizotinib
resistant pts. The median duration of treatment in the 24
evaluable ALKþ pts is 23.8þ weeks, with the longest
being 112þ weeks.
Conclusion: X-396 is well-tolerated and induces re-
sponses in both crizotinib-naïve and crizotinib-resistant
ALKþ NSCLC pts, as well as patients with CNS lesions.
Enrollment is ongoing in the expansion cohorts.
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Introduction: Approximately 30% of patients with an
adenocarcinoma have a druggable driver mutation.
However, the access to tumor tissue to perform the
molecular proﬁle is often limited. Circulating tumor DNA
(ctDNA) can be used for detection and quantiﬁcation of
molecular abnormalities as a non-invasive tool. We
performed a retrospective study to assess the concor-
dance in molecular alterations between tissue biopsies
and ctDNA in 20 NSCLC patients as well as the impact of
treatment on ctDNA proﬁle.
Methods: Plasma samples were collected from 17
consecutive treatment-naïve and 3 pre-treated advanced
NSCLC patients from Gustave Roussy. For 10 patients a
second blood sample was collected 21 days after starting
chemotherapy to monitor the mutational proﬁle. DNA
was extracted from < 3 ml plasma and analyzed using
the enhanced Tam-SeqTM assay covering regions
from 35 genes. TAM-Seq data (generated using Illuminasequencing) were compared to a different NGS platform
(Ion-torrent) as well as Sanger sequencing data from
tissue biopsy samples analyzed in routine daily clinical
practice.
Results: From May 2015 to June 2015, 20 patients were
included (70% were male, 15% never-smoker, 75% had
an adenocarcinoma subtype, and 70% a stage IV). Only
40% of tumor biopsies provided sufﬁcient sample tissue
for molecular analysis. ctDNA proﬁling was possible for
all patients, which detected cancer mutations in 19 out
of 20 patients. Median number of mutations in plasma
was 2, predominantly located in KRAS, TP53 and EGFR
mutation. Half of the mutations detected in ctDNA were
observed at a frequency lower than 1%. In 10 NSCLC
patients dynamic ctDNA changes after 21 days of treat-
ment were evaluated. No new mutations were detected
at day 21. Seven out of 10 patients experienced a partial
response in CT scan by RECIST criteria. All of them had
either a lower frequency of mutations or undetectable
levels of mutations at day 21.
Conclusions: ctDNA can be used as a ‘liquid biopsy’ for
molecular proﬁling of mutations in NSCLC patients in the
absence of an invasive biopsy with a high concordance
with tissue genomic proﬁle. Also, ctDNA can potentially
be used as a surrogate marker of response. Update in 35
patients will be presented during the conference.
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Lung cancer is the leading cause of cancer-related
deaths globally. Despite advances in treatment with
targeted therapies and earlier detection, the 5-year
survival rate remains a dismal 15%. Due to the low
survival rate, there is a critical need for new therapies
targeting lung cancer. Most lung cancers have
increased activation of Wnt signaling and/or Wnt
protein expression, which makes Wnt a strong po-
tential target for the development of new lung cancer
therapeutics. Triptolide is a natural compound isolated
from the Thunder God Vine, Tripterygium wilfordii,
which has been used in traditional Chinese medicine
to treat autoimmune disorders and inﬂammation. We
previously showed that triptolide increases WIF1
expression by decreasing WIF1 promoter methylation,
thereby inhibiting the Wnt pathway. Though triptolide
